Research Paper Volume 11, Issue 17 pp 7187—7196

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway

class="figure-viewer-img"

Figure 2. The combination of AZ628 and BP-1-102 enhanced the inhibition of KRAS mutant lung cancer cells growth. (A) Clonogenic assay was performed for KRAS(WT) H838 and KRAS(G12D) H838 cells treated with single or combination drugs. The statistical analysis was also demonstrated. * p<0.05. **p<0.01. ***p<0.001. (B) Clonogenic assay was performed for KRAS(G12S) H292 and KRAS(G12V) H441 cells treated with single or combination drugs. The statistical analysis was also tested. * p<0.05. ***p<0.001. (C) Clonogenic assay was performed for KRAS(WT) H661and H1650 cells treated with single or combination drugs. The statistical analysis was also addressed. * p<0.05. **p<0.01.